Avacta is the proprietary owner of Affimer technology for the development of biotherapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations. Avacta has made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. Meanwhile, recognition that Affimers can hit specific targets in areas where antibodies have failed, has resulted in the signing of two distinct agreements with US-based biotechs to provide highly specific Affimers for in-house research programmes.
If you'd like to be introduced to the team at Avacta Group plc, get in touch.Request a meeting